Properties of μ3 opiate alkaloid receptors in macrophages, astrocytes, and HL-60 human promyelocytic leukemia cells

M. H. Makman, Kostantin Dobrenis, C. K. Surratt

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

An opiate alkaloid-selective receptor, designated μ3, mediates inhibition by morphine of activation of human peripheral blood monocytes and granulocytes. The μ3 receptor is present on several macrophage cell types including microglia, on cultured astrocytes, and in brain and retina. Murine macrophage cell lines and human HL-60 leukemia cells contain high concentrations of these receptors. Binding of 3H-morphine to the receptor is displaced by morphine, etorphine, naloxone, diprenorphine and morphine 6- glucuronide, but not by morphine 3-glucuronide, fentanyl, benzomorphans, enkephalins, dynorphin, β-endorphin, endomorphin-1, other opioid peptides or nociceptin (orphanin FQ). The μ3 receptor appears to be much more sensitive to inactivation by reduced glutathione than are classical μ, δ and κ receptors. Evidence is also presented for G protein-coupling of these reports. These and other data raise the possibility than the μ3 receptor is a member of a chemokine or of another related receptor family, rather than the opioid receptor family. The affinity for morphine of μ3 receptors of granulocytes and granulocytic-differentiated HL-60 cells is markedly enhanced in the presence of levorphanol and certain benzomorphans. In contrast, receptors of monocytes, macrophage cell lines, microglia, macrophage- differentiated HL-60 cells and astrocytes are not affected by levorphanol or benzomorphans. It is concluded that μ3 receptors of granulocytic and promelocytic cells differ from those of macrophage and astrocyte cell types, possibly due to differences in receptor subtype or to the presence of an additional component in the granulocytic and promyelocytic cells.

Original languageEnglish (US)
Pages (from-to)137-148
Number of pages12
JournalAdvances in Experimental Medicine and Biology
Volume437
StatePublished - 1998

Fingerprint

Opiate Alkaloids
Macrophages
Opioid Receptors
Benzomorphans
Astrocytes
Leukemia
Morphine
HL-60 Cells
Levorphanol
mu Opioid Receptor
Microglia
Granulocytes
Monocytes
Diprenorphine
Etorphine
Cells
Endorphins
Dynorphins
Cell Line
Opioid Peptides

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{4d77835b14f84dadbd423dd70e7b8d9d,
title = "Properties of μ3 opiate alkaloid receptors in macrophages, astrocytes, and HL-60 human promyelocytic leukemia cells",
abstract = "An opiate alkaloid-selective receptor, designated μ3, mediates inhibition by morphine of activation of human peripheral blood monocytes and granulocytes. The μ3 receptor is present on several macrophage cell types including microglia, on cultured astrocytes, and in brain and retina. Murine macrophage cell lines and human HL-60 leukemia cells contain high concentrations of these receptors. Binding of 3H-morphine to the receptor is displaced by morphine, etorphine, naloxone, diprenorphine and morphine 6- glucuronide, but not by morphine 3-glucuronide, fentanyl, benzomorphans, enkephalins, dynorphin, β-endorphin, endomorphin-1, other opioid peptides or nociceptin (orphanin FQ). The μ3 receptor appears to be much more sensitive to inactivation by reduced glutathione than are classical μ, δ and κ receptors. Evidence is also presented for G protein-coupling of these reports. These and other data raise the possibility than the μ3 receptor is a member of a chemokine or of another related receptor family, rather than the opioid receptor family. The affinity for morphine of μ3 receptors of granulocytes and granulocytic-differentiated HL-60 cells is markedly enhanced in the presence of levorphanol and certain benzomorphans. In contrast, receptors of monocytes, macrophage cell lines, microglia, macrophage- differentiated HL-60 cells and astrocytes are not affected by levorphanol or benzomorphans. It is concluded that μ3 receptors of granulocytic and promelocytic cells differ from those of macrophage and astrocyte cell types, possibly due to differences in receptor subtype or to the presence of an additional component in the granulocytic and promyelocytic cells.",
author = "Makman, {M. H.} and Kostantin Dobrenis and Surratt, {C. K.}",
year = "1998",
language = "English (US)",
volume = "437",
pages = "137--148",
journal = "Advances in Experimental Medicine and Biology",
issn = "0065-2598",
publisher = "Springer New York",

}

TY - JOUR

T1 - Properties of μ3 opiate alkaloid receptors in macrophages, astrocytes, and HL-60 human promyelocytic leukemia cells

AU - Makman, M. H.

AU - Dobrenis, Kostantin

AU - Surratt, C. K.

PY - 1998

Y1 - 1998

N2 - An opiate alkaloid-selective receptor, designated μ3, mediates inhibition by morphine of activation of human peripheral blood monocytes and granulocytes. The μ3 receptor is present on several macrophage cell types including microglia, on cultured astrocytes, and in brain and retina. Murine macrophage cell lines and human HL-60 leukemia cells contain high concentrations of these receptors. Binding of 3H-morphine to the receptor is displaced by morphine, etorphine, naloxone, diprenorphine and morphine 6- glucuronide, but not by morphine 3-glucuronide, fentanyl, benzomorphans, enkephalins, dynorphin, β-endorphin, endomorphin-1, other opioid peptides or nociceptin (orphanin FQ). The μ3 receptor appears to be much more sensitive to inactivation by reduced glutathione than are classical μ, δ and κ receptors. Evidence is also presented for G protein-coupling of these reports. These and other data raise the possibility than the μ3 receptor is a member of a chemokine or of another related receptor family, rather than the opioid receptor family. The affinity for morphine of μ3 receptors of granulocytes and granulocytic-differentiated HL-60 cells is markedly enhanced in the presence of levorphanol and certain benzomorphans. In contrast, receptors of monocytes, macrophage cell lines, microglia, macrophage- differentiated HL-60 cells and astrocytes are not affected by levorphanol or benzomorphans. It is concluded that μ3 receptors of granulocytic and promelocytic cells differ from those of macrophage and astrocyte cell types, possibly due to differences in receptor subtype or to the presence of an additional component in the granulocytic and promyelocytic cells.

AB - An opiate alkaloid-selective receptor, designated μ3, mediates inhibition by morphine of activation of human peripheral blood monocytes and granulocytes. The μ3 receptor is present on several macrophage cell types including microglia, on cultured astrocytes, and in brain and retina. Murine macrophage cell lines and human HL-60 leukemia cells contain high concentrations of these receptors. Binding of 3H-morphine to the receptor is displaced by morphine, etorphine, naloxone, diprenorphine and morphine 6- glucuronide, but not by morphine 3-glucuronide, fentanyl, benzomorphans, enkephalins, dynorphin, β-endorphin, endomorphin-1, other opioid peptides or nociceptin (orphanin FQ). The μ3 receptor appears to be much more sensitive to inactivation by reduced glutathione than are classical μ, δ and κ receptors. Evidence is also presented for G protein-coupling of these reports. These and other data raise the possibility than the μ3 receptor is a member of a chemokine or of another related receptor family, rather than the opioid receptor family. The affinity for morphine of μ3 receptors of granulocytes and granulocytic-differentiated HL-60 cells is markedly enhanced in the presence of levorphanol and certain benzomorphans. In contrast, receptors of monocytes, macrophage cell lines, microglia, macrophage- differentiated HL-60 cells and astrocytes are not affected by levorphanol or benzomorphans. It is concluded that μ3 receptors of granulocytic and promelocytic cells differ from those of macrophage and astrocyte cell types, possibly due to differences in receptor subtype or to the presence of an additional component in the granulocytic and promyelocytic cells.

UR - http://www.scopus.com/inward/record.url?scp=0031827716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031827716&partnerID=8YFLogxK

M3 - Article

C2 - 9666265

AN - SCOPUS:0031827716

VL - 437

SP - 137

EP - 148

JO - Advances in Experimental Medicine and Biology

JF - Advances in Experimental Medicine and Biology

SN - 0065-2598

ER -